J06BB22 · Anti-infectives for systemic use
Nyxthracis (previously Obiltoxaximab SFL)
Indications
Obiltoxaximab SFL is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to Bacillus anthracis (see section 5.1). Obiltoxaximab SFL is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.1).
Composition
- Active substance
- nyxthracis
- International name (INN)
- obiltoxaximab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Nyxthracis (previously Obiltoxaximab SFL)
- Active substance
- nyxthracis
- ATC code
- J06BB22